Teratogenic potential of the newer antiepileptic drugs: What is known and how should this influence prescribing?

CNS Drugs

Volumn 16, Issue 11, 2002, Pages 755-764

  Palmieri, Carmela ^a   Canger, Raffaele ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450; FOLIC ACID ANTAGONIST; GABAPENTIN; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; SEX HORMONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ANENCEPHALUS; ANOPHTHALMIA; AORTA SUBVALVULAR STENOSIS; BIRTH DEFECT; BONE MALFORMATION; BRAIN MALFORMATION; CARDIOVASCULAR MALFORMATION; CLEFT LIP; CLEFT PALATE; CLUBFOOT; CONGENITAL MALFORMATION; CORPUS CALLOSUM AGENESIS; DOSE RESPONSE; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; ECTOPIC PREGNANCY; ECTRODACTYLY; FETOTOXICITY; FETUS MALFORMATION; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HEMIPLEGIA; HIRSUTISM; HORMONE METABOLISM; HUMAN; HYDRONEPHROSIS; HYPONATREMIA; HYPOSPADIAS; INFERTILITY; INTRAUTERINE GROWTH RETARDATION; MENSTRUATION DISORDER; NAIL HYPOPLASIA; NEURAL TUBE DEFECT; NONHUMAN; NOSE MALFORMATION; PRACTICE GUIDELINE; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; RAT; REVIEW; RISK FACTOR; SPINA BIFIDA; SPONTANEOUS ABORTION; TERATOGENICITY; URINARY TRACT MALFORMATION; VERTEBRA MALFORMATION;

EID: 0036032496     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216110-00004     Document Type: Review

References (53)

1. Morrel MJ. The new antiepileptic drugs and women: Efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia 1996; 37 Suppl. 6: S34-44
2. Finnel RH. Teratology: General considerations and principles. J Allergy Clin Immunol 1999; 103: S337-42
3. Polifka JE, Friedman JM. Clinical teratology: Identifying teratogenic risks in humans. Clin Genet 1999; 56: 409-20
4. Dencker L. Fetal development and sensitivity periods in man. In: Tomson T, Gram L, Sllanpaa M, et al., editors. Epilepsy and Pregnancy. Petersfield (UK) and Bristol (PA): Wringhtson Biomedical Publishing Ltd, 1997: 1-9
5. Kaneko S, Kondo T. Antiepileptic agents and birth defects: Incidence, mechanisms and prevention. CNS Drugs 1995; 3 (1): 41-55
6. Yerby MS. Pregnancy, teratogenesis, and epilepsy. Neurol Clin 1994; 12 (4): 749-71
7. Yerby MS. Problems and management of the pregnant women with epilepsy. Epilepsia 1987; 28 Suppl. 3: S29-36
8. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; (33): 145-58
9. Fergal D, D'Alton ME. Drugs in pregnancy: Anticonvulsants. Semin Perinatol 1997; 21 (2): 114-23
10. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344 (15): 1132-8
11. Czeizel AE, Bod M, Halasz P. Evaluation of anticonvulsant drugs during pregnancy in a population-based Hungarian study. Eur J Epidemiol 1992; 8 (1): 122-7
12. Buehler BA, Delimount D, Van Waes M, et al. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med 1990; 322 (22): 1567-72
13. Finnel RH, Buehler BA, Kerr BM, et al. Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurology 1992; 42 Suppl. 5: 25-31
14. Ogawa Y, Kaneko S, Otani K, et al. Serum folic acid in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 1991; (8): 75-8
15. Omtzigt JGC, Los FJ, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992; 42 Suppl. 5: 119-25
16. Wegner C, Nau H. Alteration of embryonic folate metabolism by valproic acid during organogenesis: Implications for mechanism of teratogenesis. Neurology 1992; 42 Suppl. 5: 17-24
17. Hernàndez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343 (22): 1608-14
18. Leppik IE. Antiepileptic drugs in development: Prospects for the near future. Epilepsia 1994; 35 Suppl. 4: S29-40
19. Glauser TA, Topiramate. Epilepsia 1999; 40 Suppl. 5: S71-80
20. Hoyme HE, Hauck L, Quinn D. Minor anomalies accompanying prenatal exposure to topiramate [abstract]. Epilepsia 1998; 56 (1): 119A
21. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: Pharmakinetics during delivery, in the neonate, and during lactation. Epilepsia 2000; 41 (6): 709-17
22. Matar KM, Nicholls PJ, Tekle A. Effects of pregnancy on the pharmacokinetics of lamotrigine in dogs. Epilepsia 1999; 40 (10): 1353-6
23. Tomson T, Ohman I, Vitols S. Lamotrigine in pregnancy and lactation: a case report. Epilepsia 1997; 38 (9): 1039-41
24. Chang SI, McAuley JW. Pharmacotherapeutic issues for women of childbearing age with epilepsy. Ann Pharmacother 1998; 32: 794-801
25. Dansky LV, Rosenblatt DS, Andermann E. Mechanisms of teratogenesis: Folic acid and antiepileptic therapy. Neurology 1992; 42 Suppl. 5: 32-42
26. Sander JWAS, Patsalos PN. An assessment on serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Res 1992; 13: 89-92
27. Sabers A, Gram L. Newer anticonvulsants: Comparative review of drug interactions and adverse effects. Drugs 2000; 60 (1): 23-33
28. Mackay FJ, Wilton LV, Pearce GL, et al. Safety of long-term lamotrigine in epilepsy. Epilepsia 1997; 38 (8): 881-6
29. Richens A. Safety of lamotrigine. Epilepsia 1994; 35 Suppl. 5: S37-40
30. Pregnancy outcomes following exposure to lamotrigine [abstract #NR277]. American Psychiatry Association Annual Meeting; 2002 May 18-23; Philadelphia, 76
31. Plains MNJ. Parke-Davis, Division of Warner-Lambert Company. (Data on file)
32. McLean MJ. Gabapentin in the management of convulsive disorders. Epilepsia 1999; 40 Suppl. 6: S39-50
33. Tecoma ES. Oxcarbazepine. Epilepsia 1999; 40 Suppl. 5: S37-46
34. Lindhout D, Hoppener RJEA, Menardi H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation of carbazepine. Epilepsia 1984; 25: 77-83
35. Bennett GD, Amore BM, Finnell RH, et al. Teratogenicity of carbazepine-10, 11-epoxide and oxcarbazepine in the SWW mouse. J Pharmacol Exp Ther 1996; 279 (3): 1237-42
36. Isojarvi JI, Pakarinen AJ, Myllyla VV. Basic haematological parameters, serum gamma-glutamyl-transferase activity, and erythrocyte folate and serum vitamin B12 levels during carbazepine and oxcarbazepine therapy. Seizure 1997; 6: 207-11
37. Pienimaki P, Lampela E, Hakkola J. Pharmacokinetics of oxcarbazepine and carbazepine in human placenta. Epilepsia 1997; 38 (3): 309-16
38. Bulau P, Paar WD, von Unruh GE. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother. Eur J Clin Pharmacol 1998; 34: 311-3
39. Andermann E. Pregnancy and oxcarbazepine. Epilepsia 1994; 35 Suppl. 3: S26
40. Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87: 224-7
41. Lindhout D, Omtzigt JGC. Pregnancy and the risk of teratogenicity. Epilepsia 1992; 33 Suppl. 4: S41-8
42. Leppik IE, Gram L, Deaton R, et al. Safety of tiagabine: Summary of 53 trials. Epilepsy Res 1999 (33); 235-246
43. Terada Y, Sato K, Funabashi H, et al. Reproduction studies of zonisamide (2): Teratogenicity study in rats (caesarean section and natural delivery studies) [in Japanese]. Jpn Pharmacol Ther 1978; 15: 4399-416
44. Terada Y, Fukagawa S, Shigematsu K, et al. Reproduction studies of zonisamide (4): Teratogenicity studies in mice, dogs and monkeys [in Japanese]. Jpn Pharmacol Ther 1987; 15: 4435-51
45. Kondo T, Kaneko S, Amano Y, et al. Preliminary report of teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 1996; 37 (12): 1242-4
46. Lindhout D, Omtzigt JGC. Teratogenic effects of antiepileptic drugs: implication for the management of epilepsy in women of the childbearing age. Epilepsia 1994; 35 Suppl. 4: 19-28
47. Tran A, O'Mahoney T, Rey E, et al. Vigabatrin: placental transfer in vivo and excretion into breast milk of the enantiomers. Br J Clin Pharmacol 1998; 45 (4): 409-11
48. Isojarvi JLT, Tapanainen JS. Valproate, hyperandrogenism, and polycystic ovaries. Arch Neurol 2000; 57: 1064-8
49. Webber MP, Hauser WA, Ottman R, et al. Fertility in persons with epilepsy: 1935-1974. Epilepsia 1986; 27: 746-52
50. Kaneko S. Epilepsy, pregnancy, and the child. Epilepsia 2000; 41 Suppl. 9: 8-13
51. Fonager K, Larsen H, Pedersen L, et al. Birth outcomes in women exposed to anticonvulsant drugs. Acta Neurol Scand 2000; 101: 289-94
52. Crawford P, Appleton R, Betts T, et al. Best practice guidelines for the management of women with epilepsy. Seizure 1999; 8: 201-17
53. Delgado-Escueta AV, Janz D. Consensus guidelines: Preconception counselling, management, and care of the pregnant women with epilepsy. Neurology 1992; 42 Suppl. 5: 149-60